reports
Old Republic International Corp: 2 directors
Two Directors at Old Republic International Corp bought/maiden bought 6,528 shares at between 29.770USD and 30.240USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...
- Jonathan Moreland
RVSB RIVERVIEW BANCORP INC.
ORI OLD REPUBLIC INTERNATIONAL CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
CVS CVS HEALTH CORPORATION
SWKS SKYWORKS SOLUTIONS INC.
CECE CECO ENVIRONMENTAL CORP.
CPZ CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
TBBK THE BANCORP
CFFI INC.
C&F FINANCIAL CORPORATION
New Mountain Finance Corporation Announces Financial Results for the Q...
NEW YORK--(BUSINESS WIRE)-- New Mountain Finance Corporation (NASDAQ: NMFC) (“New Mountain,” “New Mountain Finance” or the “Company”) today announced its financial results for the quarter ended March 31, 2024. First Quarter Highlights1 Net investment income of $37.3 million, or $0.36 per weighted average share Net asset value of $12.77 per share compared to $12.87 per share as of December 31, 2023. The 0.8% decline is driven by stable core credit performance, offset by a decrease in value in one of the Company's equity positions Internal risk rating improved with 96.5% of the portfo...
Avis Budget Group Reports First Quarter Results
Avis Budget Group Reports First Quarter Results PARSIPPANY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for first quarter 2024 today. We ended the quarter with revenues of $2.6 billion, driven by strong travel demand. Net loss was $113 million and our Adjusted EBITDA1 was $12 million. Our liquidity position at the end of the quarter was approximately $0.7 billion, with an additional $3.8 billion of fleet funding capacity. We have well-laddered corporate debt, and after giving effect to our euro note repayment in April 2024...
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Produ...
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet® NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an upd...
Avis Budget Group to Announce First Quarter 2024 Results on May 1st
Avis Budget Group to Announce First Quarter 2024 Results on May 1st Conference Call to Discuss Results Scheduled for May 2nd, 2024 PARSIPPANY, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its first quarter 2024 results after the market close on Wednesday, May 1st, 2024, and to host a conference call for institutional investors to discuss these results on Thursday, May 2nd, 2024 at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encourage...
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus ...
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobetasol propionate ophthalmic suspension 0.05% for post-surgical management of pain and inflammation; both represent large multi-million-dollar opportunitiesCompany explori...
Eyenovia to Feature its Suite of Commercial Products and the Optejet D...
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms for Mydcombi at the Vision Source Exchange, April 10-13, in Orlando NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the comp...
Moody’s rates Old Republic International’s senior unsecured notes Baa2
New York , March 25, 2024 – Moody's Ratings (Moody's) has assigned a Baa2 rating to $400 million of 10-year senior unsecured notes being issued by Old Republic International Corporation (Old Republic, NYSE: ORI). Old Republic intends to use the net proceeds from the offering to repay its 4.875% seni...
Saul Centers Inc: 1 director
A director at Saul Centers Inc bought 2,300 shares at 36.521USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results a...
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to MicroPine for progressive pediatric myopia in the U.S. and Canada Continued to advance commercial operations with launch of Mydcombi™, FDA approval of manufacturing facility, onboarding of sales organization and signing of copromotion agreement Company to host conference call and webcast today, Ma...
- Jonathan Moreland
TLYS TILLYS
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
CE CELANESE CORPORATION
BANC BANC OF CALIFORNIA INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
JFR NUVEEN FLOATING RATE INCOME FUND
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
AYX ALTERYX
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
TALO TALOS ENERGY INC.
RBB RBB BANCORP
AXR AMREP
SKYE NEMUS BIOSCIENCE INC
ELAN ELANCO ANIMAL HEALTH INC.
ANIX ANIXA BIOSCIENCES
PAYS PAYSIGN INC
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
VTN INVESCO TRUST FOR INVESTMENT G
RZLT REZOLUTE
COOK INC.
MPA TRAEGER
FRST INC.
ASLE BLACKROCK MUNIYIELD PENNSYLVANIA FD
VPV PRIMIS FINANCIAL CORP
BPRN AERSALE CORP
CRBP INVESCO PA VALUE MUNI INC TST
LSXMK BANK OF PRINCETON
BHRB CORBUS PHARMACEUTICALS HOLDINGS INC.
MDRX LIBERTY SIRIUSXM GROUP
APRE BURKE HERBERT FINANCIAL SERVICES CORP
ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
INC.
APREA THERAPEUTICS INC
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophtha...
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain follow...
- Jonathan Moreland
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
ELAN ELANCO ANIMAL HEALTH INC.
ZM ZOOM VIDEO COMMUNICATIONS
KSM INC.
VTN DWS STRATEGIC MUNICIPAL INCOME TRUST
MPA INVESCO TRUST FOR INVESTMENT G
VPV BLACKROCK MUNIYIELD PENNSYLVANIA FD
LSXMK INVESCO PA VALUE MUNI INC TST
LIBERTY SIRIUSXM GROUP
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Up...
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release financial results for the fourth quarter ended December 31, 2023 on Monday, March 18th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operati...
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clob...
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery Eyenovia plans to launch in the U.S. as soon as this summer using its Mydcombi™ sales force providing pre-surgical pupil dilation and post-surgical care in an estimated $1.3 billion annual U.S. market NEW YORK,...
American Financial Group Inc: 1 director
A director at American Financial Group Inc sold/sold after exercising options 6,159 shares at 126.805USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
New Mountain Finance Corporation Announces Financial Results for the Q...
NEW YORK--(BUSINESS WIRE)-- New Mountain Finance Corporation (NASDAQ: NMFC) (“New Mountain,” “NMFC,” “New Mountain Finance” or the “Company”) today announced its financial results for the quarter and year ended December 31, 2023. In line with preliminary estimates reported on January 18, 2024, the Company reported fourth quarter net investment income ("NII") of $0.40 per weighted average share and net asset value (“NAV”) per share of $12.87, compared to $13.06 on September 30, 2023, a decline of 0.7% excluding the impact of the $0.10 special dividend paid on December 29, 2023. The Company also...
Avis Budget Group Announces Pricing of €600 Million of Senior Notes
Avis Budget Group Announces Pricing of €600 Million of Senior Notes PARSIPPANY, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiary, Avis Budget Finance plc (the “Issuer”), priced a private offering of €600 million aggregate principal amount of 7.00% senior notes due 2029 (the “Notes”), which represents a €200 million increase from the previously announced size of the offering. The Notes will have a maturity date of February 28, 2029. The closing of the offering of the Notes is expected to occur on ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.